myoscience
Myoscience to Present at the Canaccord Genuity Musculoskeletal Conference
DGAP-News: myoscience / 25.02.2014 / 13:00 --------------------------------------------------------------------- REDWOOD CITY, Calif., 2014-02-25 13:00 CET (GLOBE NEWSWIRE) -- California based myoscience, inc., developers of the iovera°(R) system for the treatment of peripheral nerve conditions, announced today that Clint Carnell, Chairman and Chief Executive Officer, has been invited to make a presentation at the Canaccord Genuity Musculoskeletal Conference, which will be held on Tuesday, March 11, 2014 at 10:00 am CDT at the Sheraton New Orleans. ABOUT MYOSCIENCE Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy(TM), the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the iovera° system. The iovera° system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com. The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581 (c) 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. CONTACT: MEDIA RELATIONS Peter Osborne / posborne@myoscience.com News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 25.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: myoscience United States ISIN: US9902131674 End of News DGAP News-Service --------------------------------------------------------------------- 254241 25.02.2014
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden